FAM
HRTX icon

Formidable Asset Management’s Heron Therapeutics HRTX Stock Holding History

Formidable Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-700
Closed -$19K – 515
2015
Q4 		$19K Buy
+700
New +$18.7K 0.01% 305

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Formidable Asset Management's HRTX Position: Q1 2016 in Review

Formidable Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2016, closing a stake of 700 shares — an estimated $19K sold.

Formidable Asset Management first reported a position in HRTX in Q4 2015 and held it in 1 quarter. The position peaked at $19K in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q1 2016.

  • Formidable Asset Management reported no remaining Heron Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Formidable Asset Management sold 700 Heron Therapeutics shares in Q1 2016, an estimated $19K.
  • Formidable Asset Management first reported a position in Heron Therapeutics in Q4 2015 and held it in 1 quarter.
  • Formidable Asset Management's Heron Therapeutics position peaked at $19K in Q4 2015.
  • 99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2016.

Based on Formidable Asset Management's 13F filing for Q1 2016, filed 10 May 2016.